REPORT
論文・調査レポート
- 論文・学会発表【ポスター掲載】Review of real-world databases in Japan and South Korea that could be used to inform healthcare resource use and cost inputs for health economic studies
- 論文・学会発表【ポスター掲載】The impact of cost of existing treatment on the results of cost-effectiveness analysis studies for Japan
- 論文・学会発表【論文掲載】Real-world data on ranibizumab for myopic choroidal neovascularization due to pathologic myopia: results from a post-marketing surveillance in Japan
- 論文・学会発表【論文掲載】An assessment of the use of complementary and alternative medicine by Korean people using an adapted version of the standardized International questionnaire (I-CAM-QK): a cross-sectional study of an internet survey
- 論文・学会発表【論文掲載】Shared decision-making in patients with prostate cancer in Japan: patient preferences versus physician perceptions
- 論文・学会発表【論文掲載】Providing written information increases patient satisfaction: a web-based questionnaire survey of Japanese cancer survivors
- 論文・学会発表【論文掲載】Cost–utility analysis of ledipasvir/sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan
- 論文・学会発表【論文掲載】Cost-utility analysis of sofosbuvir for the treatment of genotype 2 chronic hepatitis C in Japan
- 論文・学会発表【論文掲載】Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin 5 monoclonal antibody, in healthy Japanese male subjects
- 論文・学会発表【論文掲載】日本語版EQ-5D-5Lにおけるスコアリング法の開発
- 論文・学会発表【論文掲載】Age-related difference in the sleep pressure-lowering effect between an angiotensin II receptor blocker and a calcium channel blocker in Asian hypertensives: the ACS1 study
- 論文・学会発表【ポスター掲載】Cost-Utility Analysis Of Sofosbuvir For Treatment Of Genotype2 Chronic Hepatitis C In Japan
- 論文・学会発表【論文掲載】Web-based survey on smoking cessation behaviors of current and former smokers in Japan
- 論文・学会発表【論文掲載】Effects of a sitagliptin safety alert on prescription behaviour for oral anti-hyperglycaemic drugs: a propensity score-matched cohort study of prescription receipt data in Japan
- 論文・学会発表【論文掲載】International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?